AE Wealth Management LLC Acquires 2,823 Shares of DexCom, Inc. (NASDAQ:DXCM)

AE Wealth Management LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCMGet Rating) by 296.2% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,776 shares of the medical device company’s stock after acquiring an additional 2,823 shares during the period. AE Wealth Management LLC’s holdings in DexCom were worth $281,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of DXCM. CVA Family Office LLC increased its position in DexCom by 100.0% during the second quarter. CVA Family Office LLC now owns 330 shares of the medical device company’s stock worth $25,000 after buying an additional 165 shares during the last quarter. Crewe Advisors LLC acquired a new position in shares of DexCom during the 2nd quarter valued at about $26,000. Investors Asset Management of Georgia Inc. GA ADV bought a new position in shares of DexCom in the 2nd quarter valued at approximately $33,000. Whittier Trust Co. of Nevada Inc. lifted its holdings in DexCom by 85.0% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 74 shares of the medical device company’s stock worth $38,000 after purchasing an additional 34 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. boosted its position in DexCom by 196.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 512 shares of the medical device company’s stock worth $38,000 after purchasing an additional 339 shares during the period. Institutional investors and hedge funds own 92.34% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. BTIG Research boosted their price objective on shares of DexCom to $126.00 in a research note on Tuesday, November 1st. Citigroup raised their price target on DexCom from $105.00 to $117.00 in a research report on Friday, October 28th. Stifel Nicolaus boosted their price objective on DexCom from $112.00 to $120.00 and gave the stock a “buy” rating in a research report on Friday, October 7th. Sanford C. Bernstein began coverage on DexCom in a research report on Friday, July 15th. They issued an “outperform” rating and a $105.00 price target on the stock. Finally, Raymond James increased their price objective on DexCom from $101.00 to $125.00 and gave the company an “outperform” rating in a research report on Friday, October 28th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $120.24.

DexCom Price Performance

Shares of DexCom stock opened at $115.33 on Tuesday. The firm has a market cap of $44.55 billion, a P/E ratio of 212.59, a price-to-earnings-growth ratio of 4.37 and a beta of 1.21. The firm’s 50-day simple moving average is $94.35 and its 200-day simple moving average is $86.58. DexCom, Inc. has a twelve month low of $66.89 and a twelve month high of $164.86. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.43 and a current ratio of 3.77.

Insiders Place Their Bets

In other news, Director Steven Robert Pacelli sold 1,000 shares of the stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $84.21, for a total value of $84,210.00. Following the completion of the transaction, the director now directly owns 137,700 shares of the company’s stock, valued at approximately $11,595,717. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.41% of the company’s stock.

DexCom Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Read More

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMGet Rating).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.